研究:扩大肥胖药品的医保覆盖面可能会在十年内使费用增加47.7B美元。 Study: Expanding Medicare coverage for obesity drugs could raise costs by $47.7B over a decade.

JAMA卫生论坛最近的一项研究表明,扩大GLP-1RAs等肥胖性药物的医疗保险覆盖面,可能会在10年内将医疗保险支出增加约477亿美元,尽管可能给健康带来益处。 A recent study in JAMA Health Forum indicates that expanding Medicare coverage for obesity drugs like GLP-1 RAs could increase Medicare spending by about $47.7 billion over 10 years, despite potential health benefits. 虽然更好地坚持服药可以节省保健费用,但总费用仍然很高。 While better adherence to the medication could lead to health care savings, overall costs remain high. 研究报告建议执行各种政策措施,以平衡获得机会和负担能力。 The study suggests implementing various policy measures to balance access and affordability.